A Tokyo-Based, Asian-Centered Specialty Pharma Company
Ascent Therapeutics is a privately-held, Tokyo-based, specialty pharmaceutical company.
We leverage our extensive global product development expertise and Asian footprint to efficiently develop innovative therapies in areas of high unmet medical need.
Our lead asset is IXT-m200, a monoclonal antibody in Phase 2 development for the treatment of methamphetamine addiction. Ascent has licensed the exclusive development and commercialization rights to IXT-m200 in Asia.
We are actively seeking additional partnerships and collaborations for innovative product candidates that can be developed in Asia for global markets. Contact us to further discuss potential product development collaborations.